title: Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.
abstract: OBJECTIVE
  Primary immunodeficiency diseases (PIDDs) include a large class of genetically heterogeneous disorders which predispose patients to significant risk of serious and chronic/recurrent infections, as well as reduced quality of life (QoL). Intravenous immunoglobulin (IVIG) therapy improves the well being of PIDD patients; however, the need for venous access and potentially severe side effects frequently require administration in medical facilities. We evaluated the long-term (12-month) experience with home-based self infusions of subcutaneous immune globulin (SCIG) in patients with PIDD on health-related QoL, rates of serious bacterial infections, and all other infections.
  
  
  METHODS
  Adults (n = 42) and children (n = 9) with PIDD, previously treated with clinic-based IVIG, were trained to self administer SCIG at home. QoL (SF-36(R) and CHQ-PF50 questionnaires), serious bacterial infections, serum immunoglobulin G (IgG) levels, overall infections, and incidence of adverse events were recorded at predetermined intervals.
  
  
  RESULTS
  All patients had improved perceptions of general health (adults P = 0.047, children P = 0.037). Adults also had marked improvement in the bodily pain and vitality assessments, and parents had improved perceptions of personal and family activities. Serum IgG levels were maintained at mean levels 25% higher than previous troughs on IVIG. There were 162 infections overall for an annual rate of 3.42/patient, but only 1 serious bacterial infection was observed (0.03/patient/yr). An average of 4.5 days/yr was missed from work or school per patient.
  
  
  CONCLUSIONS
  Home SCIG therapy was safe and led to improved perceptions of general health, higher serum IgG levels, and very low rates of infections and days missed from work/school.
authors.affiliation: Medical Affairs Department CSL Behring, King of Prussia, PA, USA. mel.berger@cslbehring.com
authors.forename: Melvin
authors.initials: M
authors.lastname: Berger
authors.forename: Elyse
authors.initials: E
authors.lastname: Murphy
authors.forename: Patty
authors.initials: P
authors.lastname: Riley
authors.forename: Garrett E
authors.initials: GE
authors.lastname: Bergman
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D003875:Drug Eruptions; D005260:Female; D006304:Health Status; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007136:Immunoglobulins / Q000008:administration & dosage* / Q000009:adverse effects; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy*; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000009:adverse effects; D007239:Infections / Q000453:epidemiology; D055104:Infusions, Subcutaneous; D008297:Male; D008603:Mental Health; D008875:Middle Aged; D011788:Quality of Life; D012646:Self Administration; D018582:Sick Leave
chemical_list: D007074:Immunoglobulin G; D007136:Immunoglobulins; D007155:Immunologic Factors; C510539:Vivaglobin